TELA Bio (TELA)
NASDAQ:TELA
Want to see TELA full AI Analyst Report?
Top Page
TELA Bio
(NASDAQ:TELA)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.93
▲(25.41% Upside)
Action:Reiterated
Date:06/12/26
The score is held down primarily by weak financial strength (negative equity, ongoing losses, and cash burn) and added downside risk from the Nasdaq bid-price deficiency notice. Offsetting factors include improving technical trend and a constructive earnings narrative with reiterated revenue guidance and new product/commercial execution initiatives, but near-term profitability and execution risks remain significant.
Positive Factors
Revenue Momentum
Sustained multi-year revenue growth indicates broadening adoption of TELA's reinforced tissue matrices and deeper account penetration. Durable top-line momentum supports scale benefits, increases negotiating leverage with hospitals, and underpins a plausible path to improved operating leverage as fixed costs spread.
Negative Factors
Negative Equity & Leverage
Negative equity and meaningful debt weaken financial flexibility and increase dependence on external funding. Over the medium term this elevates refinancing and covenant risk, constrains strategic optionality, and makes the company more sensitive to financing market conditions if operating cash flow doesn't improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Momentum
Sustained multi-year revenue growth indicates broadening adoption of TELA's reinforced tissue matrices and deeper account penetration. Durable top-line momentum supports scale benefits, increases negotiating leverage with hospitals, and underpins a plausible path to improved operating leverage as fixed costs spread.
Read all positive factors
TELA Bio (TELA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$36.04M
Dividend YieldN/A
Average Volume (3M)90.44K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth13.48%
EPS Growth43.42%
CountryUS
Employees209
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.79
Shares Outstanding44,766,148
10 Day Avg. Volume68,447
30 Day Avg. Volume90,440
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)8.78
Price to Sales (P/S)0.69
P/FCF Ratio-1.93
Enterprise Value/Market Cap1.53
Enterprise Value/Revenue0.68
Enterprise Value/Gross Profit1.02
Enterprise Value/Ebitda-1.70
Forecast
1Y Price Target
$2.00Price Target Upside170.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.66
Revenue Forecast (FY)$86.71M
TELA Bio Business Overview & Revenue Model
Company Description
Operating as a commercial-stage medical technology firm, TELA Bio, Inc. is dedicated to improving patient outcomes through advanced soft-tissue reconstruction solutions. Their approach emphasizes the preservation and restoration of the body's natu...
How the Company Makes Money
TELA primarily makes money by selling its surgical implant products to healthcare providers (e.g., hospitals and ambulatory surgery centers) for use in procedures such as ventral/incisional hernia repair and other abdominal wall reconstructions. R...
TELA Bio Earnings Call Summary
Earnings Call Date:May 12, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call conveyed constructive early progress with multiple meaningful positives: fully staffed U.S. commercial team, a major product launch (OviTex LTR), strong international performance (+41% in Europe), 16% unit growth, growing clinical evidence, and a board refresh to support scaling. These highlights were balanced against near-term financial pressures — modest 3% revenue growth in Q1, gross margin compression, a slightly wider net loss driven by higher interest expense, PRS utilization volatility due to concentration risk, and execution/timing risks tied to rep maturation and contract timing. Management expects an inflection in productivity as new hires reach the 6-month mark and reiterated at least 8% full-year revenue growth, signaling confidence in a stronger back half. Overall, the narrative is of early validation and building momentum, but with clear execution risks to realize the projected ramp.Positive Updates
Revenue and Guidance
Total revenue of $19.1M in Q1 2026, a 3% increase vs $18.5M in Q1 2025. Company reiterated full-year guidance of at least 8% revenue growth over 2025 and provided Q2 2026 revenue guidance of approximately $20M.
Negative Updates
Modest Overall Revenue Growth
Revenue increased only 3% YoY to $19.1M despite multiple strategic initiatives and a fully staffed salesforce, indicating early-stage commercialization headwinds and a need for the anticipated H2 ramp to achieve guidance.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue and Guidance
Total revenue of $19.1M in Q1 2026, a 3% increase vs $18.5M in Q1 2025. Company reiterated full-year guidance of at least 8% revenue growth over 2025 and provided Q2 2026 revenue guidance of approximately $20M.
Read all positive updates
Company Guidance
TELA reiterated full‑year 2026 guidance of at least 8% revenue growth over 2025 and Q2 revenue of approximately $20.0M after reporting Q1 revenue of $19.1M (up ~3% from $18.5M), driven by international sales of $3.7M (+41% YoY) and OviTex revenue of $12.6M (5,800 units, +16% YoY vs 5,000 units); OviTex PRS was $5.9M, other revenue (including LiquiFix) $0.6M (LiquiFix >50% YoY growth). Gross profit was $12.5M (gross margin 66% vs 68% a year ago, partly due to higher excess & obsolete inventory charges), total operating expenses were $23.0M (sales & marketing $16.5M, G&A $4.2M, R&D $2.3M), operating loss $10.5M, net loss $12.3M (higher interest expense $2.1M vs $1.2M prior), and cash totaled $39.5M. Management highlighted the April 1 launch of OviTex LTR, a fully resorbable hernia portfolio, a fully staffed U.S. commercial organization (greater than 90 territory managers with 19 greenfield territories), a hiring cadence where 40% of the field team was added between Q4 and Q1 (nearly three‑quarters of that cohort expected to reach six‑month breakeven by end‑Q2/start‑Q3), and said these rep maturations, contract execution timing and territory realignments are key upside/downside factors for the 8% target.TELA Bio Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
22
Negative
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 80.81M | 80.28M | 69.30M | 58.45M | 41.42M | 29.46M |
| Gross Profit | 54.35M | 54.34M | 46.49M | 40.11M | 27.04M | 18.81M |
| EBITDA | -32.52M | -32.35M | -31.68M | -40.63M | -39.06M | -29.14M |
| Net Income | -39.84M | -38.83M | -37.84M | -46.66M | -44.30M | -33.28M |
Balance Sheet | ||||||
| Total Assets | 69.89M | 81.42M | 87.33M | 78.05M | 67.86M | 62.54M |
| Cash, Cash Equivalents and Short-Term Investments | 39.54M | 50.84M | 52.67M | 46.73M | 42.02M | 43.93M |
| Total Debt | 56.39M | 55.65M | 43.06M | 42.77M | 41.46M | 31.49M |
| Total Liabilities | 75.09M | 75.11M | 58.87M | 59.17M | 53.55M | 42.45M |
| Stockholders Equity | -5.20M | 6.31M | 28.46M | 18.88M | 14.30M | 20.10M |
Cash Flow | ||||||
| Free Cash Flow | -30.20M | -28.67M | -42.58M | -41.47M | -42.62M | -31.06M |
| Operating Cash Flow | -29.66M | -28.22M | -41.59M | -40.86M | -40.75M | -30.43M |
| Investing Cash Flow | 898.00K | 846.00K | 4.45M | -599.00K | -1.87M | -627.00K |
| Financing Cash Flow | 25.57M | 25.75M | 43.06M | 46.27M | 40.85M | 585.00K |
TELA Bio Technical Analysis
Negative
0.74
Price Trends
0.85
Negative
0.81
Negative
1.05
Negative
Market Momentum
-0.02
Positive
42.82
Neutral
10.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TELA, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 0.87, below the 50-day MA of 0.85, and below the 200-day MA of 1.05, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 42.82 is Neutral, neither overbought nor oversold. The STOCH value of 10.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TELA.
TELA Bio Risk Analysis
TELA Bio disclosed 77 risk factors in its most recent earnings report. TELA Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TELA Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $53.64M | -0.98 | -82.79% | ― | 1.23% | 10.65% | |
47 Neutral | $36.04M | -1.02 | -1344.47% | ― | 13.48% | 43.42% | |
47 Neutral | $16.64M | -0.85 | -211.73% | ― | 8.92% | 17.50% | |
46 Neutral | $25.95M | -2.22 | -165.13% | ― | 7.72% | 34.39% | |
46 Neutral | $45.60M | -5.88 | -15.79% | ― | -42.94% | -529.29% | |
45 Neutral | $28.28M | -3.74 | -98.33% | ― | 4.94% | 39.27% |
* Healthcare Sector Average
TELA
TELA Bio
0.81
-1.13
-58.29%
CTSO
Cytosorbents
0.41
-0.79
-65.58%
SRTS
Sensus Healthcare
2.77
-1.94
-41.19%
NMTC
NeuroOne Medical Technologies
3.25
-0.91
-21.95%
LUNG
Pulmonx
1.27
-1.42
-52.88%
ICCM
Icecure Medical
5.93
-23.21
-79.65%
TELA Bio Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
TELA Bio Shareholders Expand Equity Incentive Plan Authorization
Positive
Jun 11, 2026
On June 9, 2026, TELA Bio stockholders approved an amendment to the company’s Amended and Restated 2019 Equity Incentive Plan, increasing the authorized shares issuable under the plan by 3,500,000 shares, with the amendment becoming effectiv...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresShareholder Meetings
TELA Bio posts modest Q1 growth, maintains 2026 outlook
Positive
May 12, 2026
TELA Bio reported first quarter 2026 revenue of $19.1 million, a 3% increase year over year with 13% unit growth, driven mainly by expanding international sales and strong European momentum, including 41% revenue growth in Europe. Despite flat ope...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
TELA Bio Reshapes Board, Appoints New Chairman, Directors
Positive
Apr 30, 2026
On April 29, 2026, TELA Bio announced a major reshaping of its board, with Chairman Doug Evans opting not to stand for re-election and to retire from the board after the 2026 Annual Meeting, alongside the post-meeting resignations of directors Kur...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
TELA Bio Posts Record 2025 Revenue, Sets 2026 Outlook
Positive
Mar 24, 2026
On March 24, 2026, TELA Bio reported that fourth-quarter 2025 revenue rose 18% year over year to a record $20.9 million and full-year 2025 revenue grew 16% to $80.3 million, driven by new customers, the U.S. launch of a larger OviTex PRS configura...
Delistings and Listing ChangesRegulatory Filings and Compliance
TELA Bio Receives Nasdaq Deficiency Notice on Listing
Negative
Mar 20, 2026
On March 17, 2026, TELA Bio disclosed that it had received a Nasdaq deficiency notice after its shares closed below the $1.00 minimum bid price for 30 consecutive business days, jeopardizing its compliance with Nasdaq Global Market listing rules. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.